Company profile for Kairos Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kairos Pharma is a clinical stage biopharmaceutical company that harnesses immunity against cancer and drug resistance. By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life. Uniquely positioned to advance our novel drug development pipeline of peptide and small molecule cancer immunotherapeutics: KROS-101, 102, 201, 301, and 401 as well as thera...
Kairos Pharma is a clinical stage biopharmaceutical company that harnesses immunity against cancer and drug resistance. By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life. Uniquely positioned to advance our novel drug development pipeline of peptide and small molecule cancer immunotherapeutics: KROS-101, 102, 201, 301, and 401 as well as therapeutic agents ENV105 and ENV205 for drug resistance.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2355 Westwood Blvd. #139 Los Angeles, CA 90064
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Kairos Pharma Provides Shareholder Update
Kairos Pharma Provides Shareholder Update

04 Nov 2025

// BUSINESS WIRE

https://www.businesswire.com/news/home/20251104131751/en/Kairos-Pharma-Provides-Shareholder-Update

BUSINESS WIRE
04 Nov 2025

https://www.businesswire.com/news/home/20251020246445/en/Kairos-Pharma-Presents-on-Phase-2-Trial-of-ENV-105-in-Advanced-Prostate-Cancer-at-European-Society-Medical-Oncologists-ESMO-Meeting

BUSINESSWIRE
20 Oct 2025

https://www.businesswire.com/news/home/20251007913966/en/Kairos-Pharma-to-Present-Positive-Safety-and-Efficacy-Data-from-Phase-2-Prostate-Cancer-Trial-at-ESMO-2025

BUSINESSWIRE
07 Oct 2025

https://www.businesswire.com/news/home/20250918393009/en/Kairos-Pharma-Announces-Positive-Interim-Efficacy-Analysis-of-Phase-2-Trial-of-ENV105-in-Advanced-Prostate-Cancer-with-Median-Progression-Free-Survival-of-Over-One-Year

BUSINESSWIRE
18 Sep 2025

https://www.businesswire.com/news/home/20250911712367/en/Kairos-Pharma-Announces-Virtual-KOL-Event-to-Provide-Perspectives-on-ENV105-Interim-Efficacy-Results-in-Advanced-Prostate-Cancer

BUSINESSWIRE
11 Sep 2025

https://www.businesswire.com/news/home/20250903169238/en/Kairos-Pharma-Announces-Presentation-of-New-Phase-1-Data-on-ENV105-Combination-Therapy-in-Non-Small-Cell-Lung-Cancer-at-the-World-Lung-Cancer-Conference-September-6-9-2025

BUSINESSWIRE
03 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty